A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT07093528
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cardiovascular Magnetic Resonance (CMR) — DIAGNOSTIC_TEST
    Patients will consent to undergo a 50-minute non-invasive stress perfusion CMR.

Study Details

To evaluate the effect of CS reducer implantation in patients with HFPEF and CMD on myocardial ischemia, measured by stress myocardial perfusion using cardiovascular magnetic resonance (CMR)

Key Dates

Start date
Oct 16, 2025
Status verified
Jan 2026
Primary completion
Aug 31, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
25 participants (estimated)

Arms

  • Arm: Heart Failure with a Preserved Ejection Fraction (HFpEF)
    Subjects with diagnosed Heart failure with a preserved ejection fraction (HFpEF), non-obstructive Coronary Artery Disease (CAD), and have documented CMD.

Primary Outcome Measure

Change in endocardial:epicardial perfusion ratio [ Time Frame: Baseline, 6 Months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo ClinicRochesterMinnesota55905
Diana Albers
[email protected]
507-255-6884
Claire Raphael, M.B.B.S., Ph.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Rochester, MN

By condition
Heart failure
By specialty
CardiologyHeart disease
By research site
Mayo Clinic· Rochester, MN

Related Studies